Latest News
- Min. Nadda Unveils ?13,000-Crore Bio-Pharma SHAKTI and Chemical Parks Push to Expand India’s Global Chemicals and Biologics Footprint
- Aurobindo Pharma Subsidiary Launches Generic Cancer Drug in US, Expands Oncology Portfolio in Global Generics Market
- KIMS Hospitals Introduces Adaptive Deep Brain Stimulation in India for Advanced Parkinson’s Treatment
Major crackdown on counterfeit medicines: Govt cancels licences of 18 pharmaceutical companies
The decision was taken by the drugs controller following inspections on 76 companies across 20 states.
- By Newsdesk
- New Delhi
- Mar 28, 2023
The Indian government has revoked the licences of 18 pharmaceutical companies for producing counterfeit medicines. According to sources, the decision was made following an inspection of 76 companies across 20 states by the Drugs Controller General of India (DCGI).
They also stated that a massive crackdown on pharmaceutical companies in the country was underway in relation to the production of bogus medicines.
According to Uzbekistan's health ministry, at least 18 children died after consuming a medicinal syrup manufactured by Indian drugmaker Marion Biotech Pvt Ltd in December.
According to the ministry, 18 of the 21 children who consumed the Doc-1 Max syrup while suffering from an acute respiratory disease died as a result of it. On the company's website, it is marketed as a treatment for cold and flu symptoms.
There had previously been allegations that four medicines manufactured by a Haryana-based pharmaceutical firm were responsible for the deaths of 66 children in The Gambia.
The World Health Organization (WHO) issued a warning in October about four cough and cold medicines made by Sonepat-based Maiden Pharmaceuticals: Promethazine Oral Solution, Kofexmalin Baby Cough Syrup, Makoff Baby Cough Syrup, and Magrip N Cold Syrup. These were identified as "substandard products" with two toxic compounds — diethylene glycol and ethylene glycol — allegedly present.